Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia

26 Oct 2022

Abstract excerpt

Genome editing of allogeneic T cells can provide “off-the-shelf” alternatives to autologous chimeric antigen receptor (CAR) T cell therapies. Disruption of T cell receptor α chain (TRAC) to prevent graft-versus-host disease (GVHD) and removal of CD52 (cluster of differentiation 52) for a survival advantage in the presence of alemtuzumab have previously been investigated using transcription activator–like effector...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36288281
DOI: 10.1126/scitranslmed.abq3010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemiaPMID 36288281Read ↗

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome.Semantic proximity Read ↗

Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic EffectsSemantic proximity Read ↗

CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapySemantic proximity Read ↗

Efficient Gene Editing of CART Cells with CRISPR-Cas12a for Enhanced Antitumor EfficacySemantic proximity Read ↗

Strengthening the CAR-T Cell Therapeutic Application using CRISPR/Cas9 TechnologySemantic proximity Read ↗

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapySemantic proximity Read ↗

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editingSemantic proximity Read ↗

Efficient gene disruption with CRISPR-Cas3 in human T cellsSemantic proximity Read ↗

Preferential disruption of HLA-A/B enhances allogeneic CAR-T cell expansion and antitumor capacity in B cell malignanciesSemantic proximity Read ↗

Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome EditingSemantic proximity Read ↗

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.